Cytokinetics (NASDAQ: CYTK) recently received a number of ratings updates from brokerages and research firms: 12/13/2016 – Cytokinetics had its “overweight” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $15.00 price target on the stock. 12/12/2016 – Cytokinetics was given a new $24.00 price target on by analysts at FBR & […]